Introduction
============

Background
----------

Ovarian cancer is the fifth most deadly form of cancer for females, after lung, breast, colon, and pancreatic cancers. It is estimated that in the United States during 2015, there will be 21,290 new cases of ovarian cancer and 14,180 deaths.[@b1-cin-suppl.5-2015-045] Standard front-line therapy for ovarian cancer consists of some form of taxane (paclitaxel) coupled with some form of platinum (cisplatin or carboplatin), hereafter referred to as platinum-based chemotherapy. Patient response to front-line therapy is not uniform. Because it is not possible to monitor a patient continually to assess response to therapy, one can use progression-free survival (PFS) or overall survival (OS) as somewhat imperfect proxies for patient response. Initially, 70%--80% of patients appear to respond to front-line therapy.[@b2-cin-suppl.5-2015-045] However, based on the TCGA database of serous ovarian carcinoma,[@b3-cin-suppl.5-2015-045] \~10% of patients have PFS of seven months or less. In contrast, \~10% of patients enjoy PFS of three years or more and the rest most ultimately relapse and die of disease progression.[@b4-cin-suppl.5-2015-045]

Therefore, it is imperative to be able to predict the responsiveness of ovarian cancer patients to front-line therapy. Our premise is that if there is a set of genetic biomarkers that are indicative of patient response, their influence is likely to be more pronounced at the two extreme ends of patient response. Therefore, if we succeed in developing one or more classifiers that are capable of discriminating between these two extreme cases, then these classifiers can be extended to encompass the entire patient population, which is precisely the objective of the present paper. We develop four different classifiers based on the TCGA Agilent data set and then validate them on the TCGA Affymetrix data set, as well as an independent data set from Tothill et al.[@b5-cin-suppl.5-2015-045]

Current status
--------------

At the moment, CA125 is the only known biomarker to assess the effectiveness of therapy in ovarian cancer. However, CA125 levels are primarily used as a post facto measure that determines whether therapy is working and not as a *predictive* indicator of whether platinum chemotherapy is likely to work. Moreover, CA125 by itself is not deemed to be sufficient as an indicator. In a recent review, it is emphasized that germline mutations in BRCA1 and BRCA2 lead to enhanced lifetime risk of developing ovarian cancer, as well as in lowering the age of initial onset of the disease.[@b6-cin-suppl.5-2015-045] Over the years, several papers have proposed various sets of biomarkers. A recent paper[@b2-cin-suppl.5-2015-045] states that "There were 139 studies that reported an association between biomarker expression and overall survival (OS) with univariate analysis, whereas with multivariate analysis, an association between biomarker expression and OS was reported in 47 studies." and "The number of studies that evaluated an association between biomarker expression and progression-free survival (PFS) with univariate analysis and multivariate analysis was 66 and 20 studies, respectively." Unless one goes through each of these studies individually, one would not know whether the analysis also incorporated additional factors, such as age, weight, number of pregnancies, stage of disease, and size of tumor.

In general, most of the papers fall into one of the two categories. In the first category, the authors have a candidate biomarker in mind. The available patient pool is divided into two groups, and the mean values of the candidate biomarker across each group are computed. If there is a statistically significant difference between these mean values (using the Student's *t*-test for example), then the candidate biomarker can be said to have passed one filter for utility. *Biomarkers* that are identified using this approach include the protein TR3 and its associated gene NR4A1,[@b7-cin-suppl.5-2015-045] Tau protein and its associated gene MAPT,[@b8-cin-suppl.5-2015-045] and *β*-tubulin and its associated gene TUBB.[@b9-cin-suppl.5-2015-045],[@b10-cin-suppl.5-2015-045] In such studies, it is implicitly assumed that only the putative biomarker being studied exhibits a significant variation across groups, while "all other things are equal." However, in the TCGA Agilent mRNA data set,[@b3-cin-suppl.5-2015-045] there are more than 200 genes that show a statistically significant difference in mean values between the two extreme cohorts (super responders \[SRs\] and nonresponders \[NRs\]). Thus, examining a few genes (or other biomarkers) in isolation may lead to incorrect conclusions.

The second approach is to apply some kind of machine learning algorithms to the data at hand, thereby obtaining a panel of biomarkers. Examples of such approaches include Ref. [@b11-cin-suppl.5-2015-045], in which 322 samples were analyzed to generate a 349-gene biomarker panel that performs very well, but when the 349 genes are reduced to 18 genes, the performance on the test data is poor,[@b12-cin-suppl.5-2015-045] in which a 300-gene Ovarian Carcinoma Index is constructed on the basis of 80 samples, which is then tested on 118 samples; and in Ref. [@b4-cin-suppl.5-2015-045], a panel of 14 genes is identified to differentiate between early relapse and late-stage relapse. It is worth pointing out that all of the abovementioned papers use some variant of the support vector machine (SVM) to find the biomarkers. Indeed, this is reasonable, as the SVM is very robust and is widely used in many application areas.

An excellent review of several studies can be found in Ref. [@b13-cin-suppl.5-2015-045]. In Ref. [@b14-cin-suppl.5-2015-045], the authors started with a set of 151 DNA repair genes and identified a subset of 23 such genes that are then used to construct a score. Within the family of DNA repair genes, it has been suggested that various genes that arise in the nucleotide excision repair and base excision repair pathways, and single-nucleotide polymorphisms in these genes, have a role to play,[@b15-cin-suppl.5-2015-045] for example, ERCC and XRCC families of genes. Finally, a BRCA2 mutation is associated with improved survival and improved chemotherapy response,[@b16-cin-suppl.5-2015-045] although mutations in BRCA1 or BRCA2 are associated with enhanced risk and earlier onset of ovarian cancer.[@b6-cin-suppl.5-2015-045] A possible explanation is that responsiveness to PARP-based therapy is enhanced with BRCA mutations. A recent paper that made an extensive and thorough benchmark study concluded that no ovarian cancer gene expression signature is ready for clinical use yet.[@b17-cin-suppl.5-2015-045] In summary, there is no shortage of claimed biomarkers. However, none of these papers contains a *molecular signature*, that is, a procedure for converting measured values of the biomarkers (usually gene expression levels) into a numerical score. The development of such a signature and not just a biomarker panel is one of the motivations behind the present paper.

Contributions of the paper
--------------------------

In the present paper, we analyze the TCGA ovarian cancer data that consists of molecular measurements and clinical outcomes on nearly 600 serous carcinomas. We study gene expression levels as molecular measurements and PFS and OS as clinical parameters. Patients whose clinical parameters (survival, OS or PFS) are at the two extremes are identified using the user-defined thresholds, as described subsequently. Then, we apply an algorithm named "lone star" developed within our research group to extract biomarkers and an associated molecular signature that can discriminate between extreme patients with respect to these clinical parameters. Then, this molecular signature is extended to the entire patient population in the TCGA study. In this manner, we are able to develop a three-way classification procedure for assigning each patient into one of the three categories, namely, SR, medium responder (MR), and NR. We also use the discriminant function developed for the extreme responders to divide the entire patient population into two groups, namely, those with a positive score and those with a negative score. Kaplan--Meier curves are plotted for these two groups, and it is shown that the patients with positive score exhibit a clear survival advantage compared to those with a negative score.

The lone star algorithm was initially presented in Ref. [@b18-cin-suppl.5-2015-045] and is described in detail in Ref. [@b19-cin-suppl.5-2015-045]. A brief description of the algorithm is given in the Approach and methods section. The source code of an MATLAB implementation of the lone star algorithm is freely available at the following URL: <http://sourceforge.net/projects/lonestar/>

Therefore, the algorithm can be readily used by even those unfamiliar with machine learning theory, without having to get into its inner workings. The biomarker panels developed on the TCGA data are then validated on an independent data set due to Ref. [@b5-cin-suppl.5-2015-045].

Approach and Methods
====================

General approach
----------------

The broad approach adopted in this paper is now described. The TCGA Agilent data set consisting of molecular measurements on roughly 600 serous ovarian carcinomas[@b3-cin-suppl.5-2015-045] is chosen as the training data set, while the corresponding TCGA Affymetrix data set[@b3-cin-suppl.5-2015-045] and the Tothill data set[@b5-cin-suppl.5-2015-045] are chosen for validating the predictions. Of note, the validation data sets also consist solely of serous carcinomas. The TCGA Affymetrix data set serves to establish that our method is portable across platforms, while the Tothill data set serves to establish that our method is portable across both platforms and data sets. Given the training data set, a number *X* between 0 and 50 is chosen. The top *X* percentile in terms of patient response is defined to be SRs and the bottom *X* percentile is defined to be NRs. Those in the middle are defined to be MRs. Of note, the best responders should be called SR and the worst responders should be called NR, while those in-between should be called MR. The precise percentile cutoff, referred to as *X* earlier, is to some extent arbitrary. We have carried out the exercise below for the values of *X* ranging from 10 percentile to 50 percentile (that is, no MR category). The choice *X* = 33, thus dividing the patients into three equal-sized groups, works best, although the results for other choices of *X* are not much different and are available from the authors. Once the three categories of patients are defined, a recently proposed algorithm,[@b18-cin-suppl.5-2015-045],[@b19-cin-suppl.5-2015-045] known as lone star, is applied to the training data, after the initially large number of features (genes) is pruned by some prefiltering. This step results in the definition of a discriminant function that is a linear combination of the expression values of the reduced feature set. The value of this discriminant function is computed for *all* patients, based on which patients are assigned to three groups: SR, MR, and NR. This results in a 3 × 3 contingency table (actual versus predicted group) and *P*-value is computed. In the next step, the patients are divided into two classes, namely, those with positive discriminant values and those with negative discriminant values. In principle, if our prediction methodology is any good, the positive class should have a survival advantage over the negative class. Kaplan--Meier curves are plotted for the two groups, and the *P*-value of the results obtained is computed for each case.

Definition of patient response
------------------------------

*Patient response* can be measured in two different ways, namely, OS and PFS. Though these two are broadly correlated, the correlation is by no means perfect. For instance, OS is determined not just by the efficacy of the therapy but also by other factors, such as age and general health. PFS is also subjective because the date on which a tumor is recorded as having progressed is the day on which it is *observed* to have progressed, whereas in reality the progression would have taken place at some unknown date between that observed date and the date of the previous checkup. Thus, the disparity between the *recorded* date of progression and the *actual* date of recurrence could be several months. It was not a priori clear which clinical parameter would lead to better predictions. Therefore, predictors were developed based on each parameter, and their performance was compared. Similarly, during the validation step too, the survival advantage of the group Δ~+~ (those with positive discriminant values) against the group Δ~−~ (those with negative discriminant values) can be computed using either OS or PFS as the clinical parameter.

Definition of extreme responders
--------------------------------

As stated earlier, patients whose survival is within the top *X* percentile are called SRs, while those in the bottom *X* percentile are called NRs. This raises the question, what value of *X* should be chosen? Very small values of *X* would cause almost all patients to be labeled as MRs, while an overly large value of *X* would cause almost no one to be classified as an MR. Various values of *X* from 10 to 50 were tried. The best results were obtained with *X* = 33%, meaning that the top one-third, middle one-third, and bottom one-third were labeled as SR, MR, and NR, respectively. Therefore, only those results are reported, though the results for other choices of *X* are available upon request.

In the TCGA database, there are 565 serous carcinoma samples for which information is available on days-to-death, days-to-recurrence, and/or days-to-last follow-up. If PFS is used as the criterion, the patients with PFS ≤283 days were classified as NRs, while patients with PFS ≥574 days were classified as SRs. If OS is used as the criterion, then patients with OS ≤504 days were classified as NR, while those with OS ≥1202 days were classified as SR. Of note, in both the TCGA Agilent and TCGA Affymetrix databases, these break points produced 189 NRs, 188 MRs, and 188 SRs. Of note, the demographic features of the three classes were quite similar. This can be ascertained from the TCGA data set. However, when the classifier was applied to the Tothill data set, the labels of NR, MR, and SR were determined solely on the basis of the survival times, both OS and PFS. Consequently, the fraction of the NR, MR, and SR samples does not necessarily correspond to the 33rd percentile.

Prefiltering the feature set
----------------------------

There are roughly 12,000 genes for which measurements are available in all three data sets (TCGA Agilent, TCGA Affymetrix, and Tothill). While developing the classifier for the training data, it is not desirable to run the lone star algorithm using all 12,000+ genes. Some prefiltering is desirable based on the combination of two attributes: (i) the *t*-test statistic that compares the mean values of a gene over the two groups and (ii) the fold change of the mean values over each group. [Figure 1](#f1-cin-suppl.5-2015-045){ref-type="fig"} illustrates the prefiltering method used. The prefiltering can either be *loose*, resulting in a large number of initial features that are then reduced further via the lone star algorithm, or be *tight*, meaning that the initial feature set passed on to the lone star algorithm is rather small.

The tight prefiltering used the following parameters: fold change of at least 1.25 between the averages of a gene's expression level over the two classes and the *P*-value of at most 0.05 between the average expression levels of the two classes, as computed using the *t*-test. This resulted in the retention of just 67 of roughly 12,000 genes for OS and 59 of roughly 12,000 genes for PFS. The loose prefiltering used the following parameters: fold change of at least 1.175 and the *P*-value of at most 0.1. This resulted in 208 genes selected for the OS and 181 genes selected for PFS.

The above discussion can be summarized in [Table 1](#t1-cin-suppl.5-2015-045){ref-type="table"}. There are four different combinations that are assessed in this paper: OS or PFS as clinical parameters and tight or loose prefiltering.

Lone star algorithm
-------------------

For each of the four situations described in [Table 1](#t1-cin-suppl.5-2015-045){ref-type="table"}, the lone star algorithm was used to develop a binary classifier to identify a handful of highly predictive features, together with an associated linear discriminant function, that could be used to distinguish between the two sets of extreme responders. The following discussion is essentially reproduced from Ref. [@b19-cin-suppl.5-2015-045] in order to make the present paper self-contained.

The lone star algorithm is a very versatile and general-purpose algorithm developed in Ref. [@b18-cin-suppl.5-2015-045] and elaborated in Ref. [@b19-cin-suppl.5-2015-045], for the purpose of identifying a small number of highly predictive features from tens of thousands of measured features. It combines various ideas in machine learning, such as the *l*~1~-norm SVM,[@b20-cin-suppl.5-2015-045] recursive feature elimination (RFE),[@b21-cin-suppl.5-2015-045] and stability selection.[@b22-cin-suppl.5-2015-045] The SVM formulation presupposes that every feature has an equal dynamic range. Therefore, for each feature, the vectors measured across all samples are converted into *Z*-scores by subtracting the mean and dividing by the standard deviation.

In case, we are given a set of labeled data here *x^i^* ∈ *R^n^* and *y~i~* ∈ {−1,1} for *i* = 1, 2, ..., *m*. Therefore, *n* denotes the number of features and *m* denotes the number of samples. The feature vector *x^i^* is viewed as a row vector. The objective is to choose a subset of features *F* ⊆ {1, ..., *n*}, a weight vector *w* ∈ *R^n^*, and a threshold *θ* ∈ *R*, such that (a) the discriminant function *f*(*x~i~*) = *x~i~w* − *θ* has the same sign as *y~i~* for most indices *i*, (b) *w~j~* = 0 for all *j* ∉ *F*, and (c) \|*F*\| ≪ *m*.

In other words, the discriminant function *f* is linear and the set of features used by the discriminant has smaller cardinality than the number of samples. Define $$P = \left\{ {i:y_{i} = 1} \right\}\ \text{and}\ N = \left\{ {i \in \ y_{i} = - 1} \right\}$$and let *m*~1~ = \|*P*\| and *m*~2~ = \|*N*\|. The algorithm consists of an iterative loop and a final classifier generation step. Steps 1--3 comprise the iterative loop, and step 4 is the final classifier generation.

Set the iteration counter to 1, the feature set *F* to the set of significant features, the feature count *s*~1~ to \|*F*\|, and the iteration count *i* to 1, and then proceed to the iterative loop. Stability selection: fix an integer *l*. Choose *k*~1~ from the *m*~1~ positive samples and *k*~2~ from the *m*~2~ negative samples at random as the *training* set of samples. Repeat this random choice *l* times, so that there are *l* different pairs of training samples: *k*~1~ from the class *P* and *k*~2~ from the class *N*. Ensure that *k*~1~ and *k*~2~ are roughly equal and lesser than *m*~1~/2 and *m*~2~/2, respectively.*l*~1~-Norm SVM: for each pair of *k*~1~ and *k*~2~ training samples, solve the following *l*~1~-norm SVM formulated in Ref. [@b20-cin-suppl.5-2015-045]: $$\min\limits_{w,\theta,y,z}\left( {1 - \lambda} \right)\left\lbrack {\alpha{\sum\limits_{j = 1}^{k_{1}}{y_{j} + \left( {1 - \alpha} \right)}}{\sum\limits_{j = 1}^{k_{2}}z_{j}}} \right\rbrack$$subject to the constraints $$\begin{array}{l}
{w^{t}x_{j} - \theta + y_{j} \geq 1,j \in P,w^{t}x_{j} - \theta - z_{j} \leq - 1,j \in N,} \\
{\mspace{142mu} y \geq 0_{k_{1}},z \geq 0_{k_{2}}.} \\
\end{array}$$The parameter *λ* should be chosen *close to* zero, but not exactly zero. The parameter *α* should be chosen as 0.5 if sensitivity and specificity are equally important. The parameter *α* should be chosen to be \<0.5 to place more emphasis on sensitivity, whereas *α* should be chosen to be \>0.5 to place more emphasis on specificity.RFE: The previous step results in *l* different optimal weight vectors, $w_{1}^{i},\ldots,w_{l}^{i}$, where *i* is the iteration count. Each weight vector will have a different number of nonzero components. Compute the average number of nonzero components, round upward to the next integer, and denote this integer as *r^i^*. Compute the average of all *l* weight vectors. Retain the *r^i^* components with the largest magnitude and discard the rest. Increase the iteration counter *i*, set *s^i^* ^+\ 1^ = *r^i^*, and proceed to step 3. If *R^i^* = *s^i^*, meaning that no features can be discarded, the iterative step is complete; hence, proceed to the next step.Final classifier generation: When this step is reached, the set of features is finalized. Run the *l*~1~-norm SVM on *l* different randomly chosen pairs of (*k*~1~, *k*~2~) training samples to generate *l* different classifiers and evaluate the performance of each of the *l* classifiers on the remaining (*m*~1~ -- *k*~1~, *m*~2~ -- *k*~2~) samples. Determine the accuracy, sensitivity, and specificity of each of the *l* classifiers. Average the weights and thresholds of the best-performing classifiers to generate an overall classifier.

Results
=======

Development of binary classifiers
---------------------------------

The lone star algorithm was applied to each of the four situations, as described in [Table 1](#t1-cin-suppl.5-2015-045){ref-type="table"}. In this subsection, the details of the resulting classifiers and their performance on the *training data set*, namely, TCGA Agilent, are given.

For PFS, with tight filtering and 59 genes as the starting point, the algorithm resulted in 25 genes being chosen as the most predictive features. For OS, 67 genes as the starting point resulted in 28 genes being chosen. The exercise was then repeated using a less aggressive or loose prefiltering step, so that the lone star algorithm has a larger number of initial features to choose. When OS was used as the criterion, the initial feature set consisted of 208 genes, of which 26 were finally chosen. When PFS was used as the criterion, the initial feature set consisted of 181 genes, of which 26 were finally chosen. Of note, though the number of finally selected features was comparable for all the four classifiers, the actual features themselves were different. [Table 2](#t2-cin-suppl.5-2015-045){ref-type="table"} lists the finally selected features in the two classifiers based on OS with tight and loose prefiltering, while [Table 3](#t3-cin-suppl.5-2015-045){ref-type="table"} lists the finally selected features in the two classifiers based on PFS with tight and loose pre-filtering. In each case, the expression values of all genes are converted into *Z*-scores by subtracting the mean and dividing by the standard deviation across all SR + NR samples. The *Z*-score of each gene is multiplied by the weight shown, and the resulting weighted sum is compared to the bias term. If the weighted sum exceeds the bias, the sample is assigned to the positive (SR) class, whereas if the weighted sum is smaller than the bias, the sample is assigned to the negative (NR) class.

For each classifier, receiver operating characteristic (ROC) curves were constructed by varying only the bias or threshold term to trade off between sensitivity and specificity. The resulting ROC curves are shown in [Figures 2](#f2-cin-suppl.5-2015-045){ref-type="fig"} and [3](#f3-cin-suppl.5-2015-045){ref-type="fig"} respectively.

3 × 3 Contingency tables
------------------------

The computations described in the previous subsection resulted in four different classifiers to discriminate between SRs and NRs. The next step was to use each of these discriminant functions and classify *all* samples into one of the *three* categories, namely, SRs, MRs, and NRs. This was done on the training data set which was TCGA Agilent and on two validation (or test) data sets, namely, the TCGA Affymetrix and Tothill. This was done as follows: The discriminant function values corresponding to all samples were computed, using the *Z*-scores of the gene expression values of the chosen features (genes). Then, the discriminant values were sorted in descending order. For the TCGA Agilent and TCGA Affymetrix data sets, the top 33% were assigned the label of SR, the bottom 33% were assigned the label of NR, and those in the middle were assigned the label of MR. These gave the predicted labels. The actual or true labels were determined by sorting the samples in terms of the OS or PFS, as the case may be, and then sorting the samples. Again, the top 33% were assigned the label of SR, the bottom 33% were assigned the label of NR, and those in the middle were assigned the label of MR. For the Tothill data set, first the number of SR, MR, and NR samples were determined based on the cutoffs of OS or PFS, as appropriate. For OS, the cutoffs were 40, 98, and 28 for SR, MR, NR, respectively. Therefore, the patients with the 40 highest discriminant scores were labeled as SR, those in the bottom 28 scores as NR, and those in-between as MR. A similar exercise was carried out for PFS times, resulting in 40, 88, and 43 for SR, MR, and NR, respectively.

For a 3 × 3 contingency table, the relevant quantity is the *P*-value of arriving at these labels purely through chance. When the total number of sample is \>50, which is the case in all of these data sets, it is possible to use the *χ*^2^ approximation to compute the *P*-values. [Tables 4](#t4-cin-suppl.5-2015-045){ref-type="table"} and [5](#t5-cin-suppl.5-2015-045){ref-type="table"} list all these values. Of note, the null hypothesis for testing contingency tables is that the labels have been assigned independently and at random, in which case the contingency table, viewed as a matrix, would be very close to a rank-one matrix. If the matrix corresponding to the contingency table is very far from being rank one, the *P*-value would be very small.

Kaplan--Meier curves
--------------------

Using the discriminant function based on the TCGA Agilent data, discriminant values were computed for all samples based on *Z*-scores for TCGA Agilent, TCGA Affymetrix, and Tothill data sets. This was done for all the four cases: OS with tight prefiltering, PFS with tight prefiltering, OS with loose prefiltering, and PFS with loose prefiltering. Patients were divided into two groups: with positive discriminant value and with negative discriminant value. Kaplan--Meier curves were plotted to see whether the survival (OS or PFS, as appropriate) between these two groups was statistically significant. [Figures 4](#f4-cin-suppl.5-2015-045){ref-type="fig"} through [7](#f7-cin-suppl.5-2015-045){ref-type="fig"} show the results, including the *P*-values of obtaining the separation between classes purely by chance.

Discussion
==========

We begin with a discussion of the three sets of findings, namely, the ROC curves, the 3 × 3 contingency tables, and the Kaplan--Meier curves. Then, we present an overall discussion.

From the four ROC curves, two broad conclusions can be drawn: Classifiers based on OS to define the classes perform slightly worse than classifiers based on PFS.The classifiers based on loose prefiltering perform better on the training data but slightly worse on the testing data.

For the 3 × 3 contingency tables, where the results of assigning *all* patients to one of the three categories (SR, MR, and NR) are reported, the broad conclusions are as follows: When OS is used as the clinical parameter, the classifier performs satisfactorily on the TCGA Affymetrix test data; however, it performs poorly on the independent Tothill data set despite the prefiltering of the genes is tight or loose. Therefore, OS does not appear to provide a useful clinical parameter for this purpose. In contrast, if PFS is used as the clinical parameter, then the *P*-value on the TCGA Affymetrix data set is below machine zero despite the prefiltering is tight or loose. On the independent Tothill data set, the classifier based on tight prefiltering achieves a *P*-value of 0.0313. When loose prefiltering is used, the classifier based on PFS achieves a *P*-value of 0.0319. Given that a *P*-value of 0.05 is widely accepted in biological circles as a benchmark for statistical significance, it can be said that the three-way classification substantially outperforms chance on both the TCGA Affymetrix and Tothill data sets, when PFS is used as the clinical parameter to define the responder classes. Therefore, PFS appears to be a useful clinical parameter that can be used to predict overall patient response.

For the Kaplan--Meier curves, where the entire patient population is divided into two groups, these are the broad conclusions: on the training data consisting of the TCGA Agilent database, the group with a positive score shows a very significant survival advantage over the group with a negative score. However, on the independent validation data set, namely, the Tothill data set, once again the use of OS as the clinical parameter does not lead to satisfactory results.

In contrast, when PFS is used as the clinical parameter, the *P*-value of the Kaplan--Meier curves using the log-rank test is \<0.001 with tight prefiltering and \<0.006 with loose prefiltering. Both the values are far lower than the widely accepted threshold of 0.05. Therefore, PFS appears to be a useful clinical parameter for assigning a numerical score to predict patient response.

Now we make some general comments on the outcomes of this paper. The motivation for this research was to determine whether it is possible to predict the response of ovarian cancer patients to front-line platinum chemotherapy using the biomarkers extracted in a purely data-driven fashion via machine learning algorithms. The results are mixed. From the standpoint of considerably outperforming chance, it is unmistakably clear that the biomolecular signatures based on PFS developed here perform spectacularly well on the training data set (TCGA Agilent) as well as one validation data set (TCGA Affymetrix) and also achieve *P*-values \<0.05 on an independent Tothill data set. For the 3 × 3 contingency tables, on an entirely independent validation data set (Tothill), the *P*-values are \~0.03 if PFS is used as the clinical parameter. Similarly, the *P*-values of the Kaplan--Meier curves are also \<0.006. Therefore, these findings serve to establish that PFS is a very useful clinical parameter that can be used for predicting patient response.

It would be highly desirable to test whether the performance on the Tothill data set could be repeated on other data sets. Unfortunately, in ovarian cancer, there very few large data sets that contain detailed information on the OS and/or PFS of patients. There is one data set, known as the Yoshihara data set, which consists of about 100 samples, and the rest contain fewer than 50 samples. With very few samples, it is not realistic to expect that classifiers would demonstrate a statistically significant improvement over pure chance. Thus, we are forced to remain content with just one independent validation data set, on which the approach leads to good results from the standpoint of statistical significance.

Along similar lines, we have not been able to locate any other molecular signature that can be readily applied to gene expression data, whose predictions can be compared with those given here. The available literature on the topic consists of biomarker panels, that is, lists of genes, but not a numerical procedure for combining the expression values of these genes to assign patients to two or more categories, as is done here.

From the standpoint of being useful in clinical practice, there is considerable scope for improvement. Ideally, the 3 × 3 contingency tables should assist the physician to assign a patient to an appropriate category. If a patient can be said to be an NR with high confidence, then she could straightaway be given alternative therapy. Similarly, if a patient can be said to be an SR with high confidence, the physician can proceed with front-line therapy in an aggressive manner. However, [Tables 6](#t6-cin-suppl.5-2015-045){ref-type="table"} and [7](#t7-cin-suppl.5-2015-045){ref-type="table"} show that the positive predictive value of these categorizations *on the validation data sets* is only \~50% or less. Thus, more work is needed to improve these predictions. In other words, an approach can lead to results that are *statistically significant* while not yet being useful in a clinical setting.

One of the objectives of the present paper was to compare OS with PFS as the clinical parameter to categorize a patient. It would appear a priori that OS is a more *reliable* parameter because there is absolutely no ambiguity about the time of death of a patient (assuming that the clinic has not lost track). On the other hand, as pointed out earlier, the actual date of tumor progression lies somewhere between the *reported* date of tumor progression and the date of the previous checkup. Therefore, it is surprising that in all the various tests performed, the classifiers based on PFS as the clinical parameter outperform the ones based on OS. One possible explanation is that OS is determined as a whole host of factors, such as age and grade of tumor not just by the gene expression level, and in this sense, PFS is more robust against variations in these additional factors. However, this hypothesis needs to be assessed by gynecological oncologists. Furthermore, it may be desirable to enlarge the set of features beyond gene expression levels by also including other factors, such as age and grade of tumor. For such a study to be meaningful, the number of tumors needs to be an order of magnitude greater than 565, which is available in the TCGA data set.

The predictive features generated in this paper are obtained by using the lone star algorithm,[@b18-cin-suppl.5-2015-045] which does not make any use of pathway information or any other contextual information about various features. Other work carried out by a subset of the authors has led to an algorithm known as "phixer" that can be used to reverse engineer whole-genome context-sensitive gene interaction networks. Future work by our research team would consist of combining these two algorithms so as to choose features that are both highly predictive and also interpretable in terms of biological pathways.

A recent paper on melanoma[@b23-cin-suppl.5-2015-045] suggests that there are different evolutionary trajectories for different subtypes. This is a very significant observation, and it is likely that similar conclusions might apply to other forms of cancer, though this is yet to be established. If differences in patient responses in ovarian cancer were to be the result of tumors in different patients following different evolution trajectories, the complexity of the disease would increase enormously; in turn, this would make it more difficult to apply machine learning methods of the type used in the present paper.

Conclusions
===========

In this paper, we have proposed a methodology for grouping ovarian cancer patients into three categories, referred to here as SRs, MRs, and NRs, in terms of their response to front-line platinum chemotherapy. We have also developed an approach for grouping patients into two groups in such a way that one group has a statistically significant survival advantage over the other. While both approaches achieve *P*-values far below the widely accepted threshold of 0.05, further work is required to make this approach useful in a clinical setting.
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![Volcano plot of the negative logarithm of the *t*-test scores on the vertical axis and the fold changes on the horizontal axis.](cin-suppl.5-2015-045f1){#f1-cin-suppl.5-2015-045}

![ROC curves with tight prefiltering. Both classifiers started with 59 initial features, of which each classifier chose 25 features (which are different from one case to the other). (**A**) OS as the clinical parameter and (**B**) PFS as the clinical parameter.](cin-suppl.5-2015-045f2){#f2-cin-suppl.5-2015-045}

![ROC curves with loose prefiltering. (**A**) The results using OS as the clinical parameter. The initial number of features was 208, of which 26 features were chosen finally. AUCs of the three curves are 0.8922, 0.6833, and 0.5781. (**B**) The results using PFS as the clinical parameter. The initial number of features was 181, of which 26 features were finally chosen. AUCs of the three curves are 0.8721, 0.6683, and 0.6886.](cin-suppl.5-2015-045f3){#f3-cin-suppl.5-2015-045}

![Kaplan--Meier curves for classifier using OS to define classes and tight prefiltering. *P*-values are computed using log-rank test.](cin-suppl.5-2015-045f4){#f4-cin-suppl.5-2015-045}

![Kaplan--Meier curves for classifier using OS to define classes and loose prefiltering. *P*-values are computed using log-rank test.](cin-suppl.5-2015-045f5){#f5-cin-suppl.5-2015-045}

![Kaplan--Meier curves for classifier using PFS to define classes and tight prefiltering. *P*-values are computed using log-rank test.](cin-suppl.5-2015-045f6){#f6-cin-suppl.5-2015-045}

![Kaplan--Meier curves for classifier using PFS to define classes and loose prefiltering. *P*-values are computed using log-rank test.](cin-suppl.5-2015-045f7){#f7-cin-suppl.5-2015-045}

###### 

The four classifiers studied in this paper.

  CLASSIFIER NO.     CLINICAL PARAMETER          PRE-FILTERIN
  ------------------ --------------------------- --------------
  Classifier No. 1   Overall survival            Tight
  Classifier No. 2   Overall survival            Loose
  Classifier No. 3   Progression-free survival   Tight
  Classifier No. 4   Progression-free survival   Loose

###### 

Classifier nos. 1 and 2 -- classifiers for OS.

  ENTREZ GENE ID   GENE SYMBOL   WEIGHT    ENTREZ GENE ID   GENE SYMBOL   WEIGHT
  ---------------- ------------- --------- ---------------- ------------- ---------
  241              ALOX5AP       −0.5630   953              ENTPD1        −0.7066
  3764             kcnj8         −0.4870   54704            Pdp1          −0.6358
  26290            GALNT8        −0.4393   1410             CRYAB         −0.5821
  25790            Ccdc19        −0.3118   3764             kcnj8         −0.4942
  2857             GPR34         −0.3116   5266             PI3           −0.4846
  8483             CILP          −0.3039   25790            Ccdc19        −0.4362
  794              CALB2         −0.2889   6236             RRAD          −0.4067
  55016            MARCH1        −0.2662   10218            angptl7       −0.3554
  6356             Ccl11         −0.2458   26290            GALNT8        −0.3522
  64231            MS4A6A        0.1312    9033             pkd2l1        −0.3252
  25924            MYRIP         0.2086    10753            Capn9         0.2204
  962              Cd48          0.2207    728621           CCDC30        0.2306
  10753            Capn9         0.2422    57612            KIAA1466      0.2680
  51284            TLR7          0.2827    3918             LAMC2         0.3141
  1634             DCN           0.2845    404093           CUEDC1        0.3931
  123872           LRRC50        0.2881    4147             Matn2         0.3981
  79623            Galnt14       0.2937    1674             DES           0.4020
  26585            GREM1         0.3075    203102           ADAM32        0.4241
  5016             Ovgp1         0.3079    5521             PPP2R2B       0.4337
  5276             serpini2      0.3439    9450             LY86          0.4763
  6387             CXCL12        0.3519    8470             SORBS2        0.4815
  56143            PCDHA5        0.3777    135138           Pacrg         0.5750
  135138           Pacrg         0.3992    7130             TNFAIP6       0.5876
  4147             Matn2         0.4722    1118             CHIT1         0.6102
  1118             CHIT1         0.4867    1360             Cpb1          0.6115
                                           23144            ZC3H3         0.7026
                   Bias          0.0150                     Bias          0.0924

###### 

Classifier nos. 3 and 4 -- classifiers for PFS.

  ENTREZ GENE ID   GENE SYMBOL   WEIGHT    ENTREZ GENE ID   GENE SYMBOL   WEIGHT
  ---------------- ------------- --------- ---------------- ------------- ---------
  26290            GALNT8        −0.3878   3696             ITGB8         −0.5790
  79908            BTNL8         −0.3711   1301             COL11A1       −0.5332
  6356             Ccl11         −0.3313   1421             CRYGD         −0.5161
  8483             CILP          −0.3161   219699           Unc5b         −0.4445
  2043             EPHA4         −0.3061   27010            TPK1          −0.4264
  1421             CRYGD         −0.2971   79908            BTNL8         −0.3970
  23148            NACAD         −0.2522   79933            SYNPO2L       −0.3925
  27010            TPK1          −0.2273   8483             CILP          −0.3620
  54532            usp53         −0.2214   55083            KIF26B        −0.2996
  1281             COL3A1        −0.1851   27335            EIF3K         −0.2712
  1301             COL11A1       −0.0626   65263            PYCRL         −0.2676
  29989            OBP2B         0.0028    898              CCNE1         0.2501
  26576            SRPK3         0.1299    79815            NIPAL2        0.2547
  26585            GREM1         0.1378    64220            STRA6         0.2579
  8842             PROM1         0.1870    10017            Bcl2l10       0.3016
  203102           ADAM32        0.1898    203102           ADAM32        0.3387
  4222             meox1         0.2153    64067            Npas3         0.3950
  79623            Galnt14       0.2268    6361             Ccl17         0.4034
  10017            Bcl2l10       0.2286    79696            Fam164c       0.4242
  1896             eda           0.2519    50626            CYHR1         0.4313
  29991            OBP2A         0.2629    3752             Kcnd3         0.4829
  64067            Npas3         0.2664    6778             STAT6         0.4922
  122616           C14orf79      0.2947    6387             CXCL12        0.5239
  4147             Matn2         0.3110    56143            PCDHA5        0.5241
  1634             DCN           0.3338    8842             PROM1         0.5826
  9723             Sema3e        0.3420    1290             Col5a2        0.7540
  56143            PCDHA5        0.4219                                   
  6361             Ccl17         0.4895                                   
                   Bias          0.0084                     Bias          −0.0189

###### 

Three-way classification based on OS and tight prefiltering.

  LABEL            TCGA AGILENT    TCGA AFFYMETRIX              TOTHILL                                                                                            
  ---------------- --------------- ---------------------------- -------------------- ----------- -------- -------- -------- ----------- -------- -------- -------- -----------
  **Pred./Act.**   **SR**          **MR**                       **NR**               **Total**   **SR**   **MR**   **NR**   **Total**   **SR**   **MR**   **NR**   **Total**
  **SR**           107             57                           24                   188         89       59       39       188         13       29       6        48
  **MR**           66              67                           56                   189         64       64       60       188         27       57       14       98
  **NR**           15              64                           109                  188         34       65       88       189         8        12       8        28
  **Total**        188             188                          188                  565         187      188      187      565         48       98       28       174
  ***P*-Value**    *P*-Value = 0   *P*-Value = 6.041 × 10^−9^   *P*-Value = 0.3532                                                                                 

###### 

Three-way classification based on OS and loose prefiltering.

  LABEL            TCGA AGILENT    TCGA AFFYMETRIX   TOTHILL                                                                                            
  ---------------- --------------- ----------------- -------------------- ----------- -------- -------- -------- ----------- -------- -------- -------- -----------
  **Pred./Act.**   **SR**          **MR**            **NR**               **Total**   **SR**   **MR**   **NR**   **Total**   **SR**   **MR**   **NR**   **Total**
  **SR**           117             58                13                   188         79       59       49       187         11       25       4        40
  **MR**           60              63                66                   189         76       62       50       188         24       48       18       90
  **NR**           11              67                110                  188         32       67       88       187         13       25       6        44
  **Total**        188             188               189                  565         187      188      187      562         48       98       28       174
  ***P*-Value**    *P*-Value = 0   *P*-Value = 10    *P*-Value = 0.1077                                                                                 

###### 

Three-way classification based on PFS and tight prefiltering.

  LABEL            TCGA AGILENT    TCGA AFFYMETRIX   TOTHILL                                                                                            
  ---------------- --------------- ----------------- -------------------- ----------- -------- -------- -------- ----------- -------- -------- -------- -----------
  **Pred./Act.**   **SR**          **MR**            **NR**               **Total**   **SR**   **MR**   **NR**   **Total**   **SR**   **MR**   **NR**   **Total**
  **SR**           110             54                24                   188         85       63       39       188         15       18       7        40
  **MR**           59              66                62                   189         61       62       63       189         20       48       20       88
  **NR**           18              67                103                  188         40       60       87       188         4        24       15       43
  **Total**        187             187               185                  565         186      185      189      565         39       90       42       171
  ***P*-Value**    *P*-Value = 0   *P*-Value = 0     *P*-Value = 0.0313                                                                                 

###### 

Three-way classification based on PFS and loose prefiltering.

  LABEL            TCGA AGILENT    TCGA AFFYMETRIX   TOTHILL                                                                                          
  ---------------- --------------- ----------------- ------------------ ----------- -------- -------- -------- ----------- -------- -------- -------- -----------
  **Pred./Act.**   **SR**          **MR**            **NR**             **Total**   **SR**   **MR**   **NR**   **Total**   **SR**   **MR**   **NR**   **Total**
  **SR**           114             58                16                 188         84       60       43       187         12       22       6        40
  **MR**           62              66                59                 187         64       64       58       186         23       46       19       88
  **NR**           11              63                114                188         38       61       88       187         4        22       17       43
  **Total**        187             187               189                563         186      185      189      560         39       90       44       171
  ***P*-Value**    *P*-Value = 0   *P*-Value = 0     *P*-Value 0.0319                                                                                 
